About Anthem Biosciences IPO
The IPO is an Provide for Sale (OFS) and contains stake sale aggregating as much as Rs 350 crores every by Ganesh Sambasivam and Okay Ravindra Chandrappa who’re promoter promoting shareholders. As much as Rs 1,325 crores will likely be offloaded by Viridity Tone LLP and as much as Rs 320 crores by Portsmouth Applied sciences LLC (Investor Promoting Shareholders).
It additionally contains stake gross sales of Rs 320 crores every by Malay J Barua, Rupesh N Kinekar and Satish Sharma, as much as Rs 80 crore by Prakash Kariabettan and as much as Rs 10 crore by Okay Ramakrishnan.
About Anthem Biosciences
Anthem’s enterprise contains Contract Analysis, Improvement and Manufacturing Group (CRDMO) providers and the manufacture and sale of specialty elements. It provides a complete, built-in and extremely customizable vary of CRDMO providers throughout the New Chemical Entity (NCE) and New Organic Entity (NBE) lifecycles.
The corporate claims to have a robust presence throughout numerous modalities, akin to RNAi, ADC, peptides, lipids and oligonucleotides, and manufacturing methods, akin to circulation chemistry, enzymatic processes, biocatalysis and fermentation, providing a broad vary of expertise capabilities for drug growth.
It additionally manufactures and sells advanced specialised fermentation-based Lively Pharmaceutical Elements (APIs), together with probiotics, enzymes, peptides, dietary actives, vitamin analogues and biosimilars.
Ajay Bhardwaj (Chairman, MD & CEO), Ganesh Sambasivam (Complete-time Director and Chief Scientific Officer), Okay Ravindra Chandrappa (Complete-time Director and Chief Working Officer) and Ishaan Bhardwaj (Vice President) are the Promoters of the corporate.The corporate, which was integrated in 2006, has two operational manufacturing amenities in India, Unit I (Bommassandra) and Unit II (Harohalli), each in Karnataka, with an mixture annual customized synthesis capability of 270 kL and fermentation capability of 142 kL, as of March 31, 2025.In accordance with the RHP, the corporate is within the means of increasing its customized synthesis capability at Unit II (Harohalli) by 130 kL in addition to increasing its customized synthesis capability by 25kL and fermentation capability by 40kL by developing Unit III (Neoanthem Lifesciences Personal Restricted, wholly-owned Subsidiary), each anticipated to be totally operational by the primary half of Fiscal 2026.
Put up-expansion actions, the combination annual customized synthesis capability and fermentation capability is anticipated to extend to 425 kL and 182 kL, respectively. The fermentation capability of 182 kL is anticipated to be greater than six occasions the capability of the second largest participant on this trade, based on the F&S Report.
Anthem Biosciences financials
Its income from operations elevated by 30% to Rs 1,844 crores in FY25 from Rs 1,419 crores in FY24. The PAT for the yr ended March 31, 2025 was Rs 451 crores, a soar of twenty-two.86% over FY24.
Sai Life Sciences Restricted, Syngene Worldwide Restricted, Cohance Lifesciences Restricted, (Previously Suven Prescribed drugs) and Divi’s Laboratories Restricted are the listed friends of Anthem Biosciences, as per its RHP.
Anthem Biosciences lead managers
The E-book Working Lead Managers to the supply are JM Monetary Restricted, Citigroup World Markets India Personal Restricted, J.P. Morgan India Personal Restricted and Nomura Monetary Advisory and Securities (India) Personal Restricted.
The fairness shares are proposed to be listed on BSE and NSE.
(Disclaimer: Suggestions, solutions, views and opinions given by the consultants are their very own. These don’t signify the views of Financial Occasions)
